Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSMI-4b is a potent, selective small molecule inhibitor of the enzyme O-linked N-acetylglucosamine transferase (OGT). It has an EC50 of approximately 3 μM in cells and is considered one of the most effective cell-active inhibitors for probing the biological functions of OGT. By inhibiting OGT, it reduces protein O-GlcNAcylation—a post-translational modification involved in numerous cellular processes including signaling, transcription regulation, and stress response. The compound was discovered through high-throughput screening and further optimized for potency. While highly useful as a research tool to study epigenetics and cell signaling pathways involving protein glycosylation, its physicochemical properties currently limit its development as a therapeutic drug candidate[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OSMI-4b.